# Epitalon FAQ: Telomerase, Spelling, Dosing, Safety, and Regulatory Status > Epitalon frequently asked questions: what the AEDG tetrapeptide is, how it differs from Epithalamin, what dosing has been used in studies, what side effects have been reported, and where the literature's limits actually fall. The questions actually asked about Epitalon — definitional, mechanistic, dosing, safety, regulatory — answered in 40-80 words each, with every quantitative claim cited. ## Definitional ### What is Epitalon? Epitalon is a synthetic tetrapeptide with sequence Ala-Glu-Asp-Gly (AEDG), developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology from the amino-acid composition of the bovine pineal extract Epithalamin [1][14]. It is studied as a putative telomerase activator and as a candidate geroprotector in rodent models [2][15]. It is not an FDA-approved drug for any human indication. ### What is the difference between Epitalon and Epithalon? They are the same tetrapeptide (Ala-Glu-Asp-Gly). 'Epithalon' is the more common transliteration from the Russian literature and the spelling preferred by most peptide databases. 'Epitalon' is the simplified spelling used by Wikipedia and embedded in this domain [15]. Both spellings appear in the PubMed record, sometimes within the same paper [1][4]. ### What is the difference between Epitalon and Epithalamin? Epithalamin is a crude polypeptide extract of bovine pineal gland — a complex biological mixture. Epitalon is the synthetic defined-sequence tetrapeptide AEDG, designed to reproduce a portion of Epithalamin's activity in a chemically clean form [14]. Most published human-cohort melatonin data is on Epithalamin, not on the synthetic tetrapeptide [11]. ### What is the difference between Epitalon and Epithalone? All three — Epitalon, Epithalon, Epithalone — are spellings of the same AEDG tetrapeptide. 'Epithalon' and 'Epithalone' are transliterations from Cyrillic; 'Epitalon' is the simplified English form Wikipedia uses [15]. The variant terminal 'e' in 'Epithalone' appears in some older Russian-program review articles; the molecule is identical. ### What is the AEDG peptide? AEDG is the single-letter shorthand for the amino-acid sequence of Epitalon: Alanine-Glutamate-Aspartate-Glycine. Researchers and chemists use 'AEDG peptide' and 'Epitalon' interchangeably in the peer-reviewed literature [1][3][15]. The molecule is a linear tetrapeptide with molecular formula `C14H22N4O9` and molar mass 390.35 g/mol. ### What is Epitalon's chemical structure? Tetrapeptide with sequence H-Ala-Glu-Asp-Gly-OH. Molecular formula `C14H22N4O9`, molar mass 390.35 g/mol, CAS 307297-39-8 for the TFA salt commonly used in research [15]. It is a short linear peptide without disulfide bridges or other post-translational modifications. ### What is the chemical formula of Epitalon? Molecular formula `C14H22N4O9`. Molar mass 390.35 g/mol. CAS registry 307297-39-8 for the TFA salt commonly used in research synthesis [15]. The molecule is a four-amino-acid linear peptide (Ala-Glu-Asp-Gly) with no post-translational modifications. ## Mechanism ### What does Epithalon peptide do? In vitro work shows induction of telomerase activity and telomere elongation in human somatic cell lines — first reported by Khavinson, Bondarev and Butyugov in 2003 and independently replicated by Al-dulaimi and colleagues in *Biogerontology* in 2025 [1][2]. Animal work suggests effects on melatonin rhythms, antioxidant pathways, and spontaneous tumor incidence in rodent geroprotection models [4][6][7]. ### How does Epitalon activate telomerase? Proposed model: AEDG binds to specific gene promoter regions and to histone proteins (notably H1/3 and H1/6 at their DNA-interactive sites), increasing hTERT expression and leading to elongation of telomeric repeats in cultured human cells [1][3]. The mechanism remains under active investigation; the 2025 Araj review identifies the precise binding-and-transcription cascade as an outstanding question [15]. ### What is the mechanism of action of Epitalon? Proposed mechanisms include direct binding to specific DNA promoter regions, induction of hTERT expression and telomerase activity, restoration of pineal melatonin circadian rhythm in pineal-hypofunctional subjects, and modulation of antioxidant defence markers [1][3][11][15]. The 2020 *Molecules* paper proposed a histone-binding epigenetic refinement based on molecular modelling [3]. ## Evidence ### What are the benefits of Epithalon in the research literature? Studied effects in the peer-reviewed record include telomerase induction in human cell lines [1][2], reduced spontaneous tumor frequency in HER-2/neu mice [4][5], suppressed colon carcinogenesis in rats [8], slowed reproductive ageing in SHR mice [6], and melatonin-rhythm normalisation in elderly subjects with pineal hypofunction [11]. Human data is limited to small, mostly Russian-language cohort studies. ### Has Epitalon been studied in humans? Yes — primarily in Russian-language cohort studies coordinated by the Khavinson group, with reported endpoints around melatonin circadian rhythm and elderly geriatric function [11][12]. A small parabulbar-injection series in retinitis pigmentosa patients also exists [13]. Large, modern, registered Western randomised controlled trials are absent from ClinicalTrials.gov as of 2026 [15]. ### Has Epitalon been studied in animal models? Yes — multiple rodent studies report effects on spontaneous tumor frequency [4][5][7], DMH-induced colon carcinogenesis [8], reproductive ageing and chromosome-aberration frequency [6], maximum lifespan in senescence-accelerated mice [9], and survival under altered illumination regimes [10]. Most published in *Bulletin of Experimental Biology and Medicine* and English-language Khavinson-program reviews [14]. ### What does the most recent research on Epitalon show? Two 2025 papers anchor the modern reading. Al-dulaimi and colleagues in *Biogerontology* independently replicated telomere elongation in normal human cell lines via hTERT upregulation, with selective ALT-pathway activation in breast cancer lines [2]. The Araj review in *International Journal of Molecular Sciences* consolidated twenty-five years of evidence and identified pharmacokinetics, toxicology, and modern human trials as outstanding gaps [15]. ### What is Epitalon used for in research? In the peer-reviewed literature, Epitalon is used as a research probe for telomerase activation in human cell lines [1][2], pineal melatonin regulation in aged subjects [11][12], antitumor effects in rodent geroprotection models [4][7][8], and biomarkers of cellular ageing including hTERT expression, telomere length, and oxidative-stress indices [15]. ### Who developed Epitalon? Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology synthesised Epitalon in the late 1980s and 1990s, designed from the amino-acid composition of the bovine pineal extract Epithalamin [1][14]. Khavinson's 2002 *Neuro Endocrinology Letters* supplement-length monograph 'Peptides and Ageing' remains the program's narrative summary [14]. ## Dosing and pharmacokinetics ### What dosing regimens have been used in Epitalon studies? Rodent protocols commonly report 0.1 to 1.0 microgram per mouse subcutaneous, 5 consecutive days per month, across years of life [4][6][7]. Russian human-cohort reports describe intramuscular courses of the parent extract Epithalamin — typically around 10 mg per injection, 5 injections per course, repeated periodically [11]. All described as published study dosing, not as clinical recommendation. ### What is Epitalon's half-life? Validated plasma half-life data for the intact tetrapeptide is sparse in PubMed-indexed literature. As a short, unmodified linear peptide, rapid serum proteolysis is expected — clearance on the order of minutes to low single-digit hours [15]. The 2025 Araj review identifies pharmacokinetic characterisation as an outstanding research gap; no formal validated PK data in humans is published [15]. ### How long does Epithalon take to work? Published studies describe outcome measures evaluated over weeks to months following a short injection course; in vitro telomere-elongation work shows effects across multiple cell-division cycles [1][2]. There is no validated 'onset' figure for clinical effect in the modern indexed Western literature, and the 2025 Araj review explicitly flags the absence of formal PK/PD characterisation [15]. ### Time course of effects in studies In the rodent geroprotection record, outcome measures (tumor frequency, reproductive cycling, cytogenetic damage) are typically evaluated over months of monthly 5-day dosing across years of animal life [4][6][7]. In the elderly-cohort melatonin work, effects on nocturnal melatonin secretion are reported following short intramuscular Epithalamin courses on the order of 5 injections per course [11]. ### Cosmetic / appearance claims Does Epitalon make you look younger? Cosmetic claims about appearance are not the primary endpoint of the peer-reviewed Epitalon literature, which focuses on cellular and molecular markers (telomerase activity, telomere length, melatonin secretion, oxidative-stress indices) [1][2][11][15]. Anecdotal appearance reports in consumer media are not validated by clinical trial endpoints in the published record. ### Does Epitalon actually work? What does the evidence actually show? In vitro: replicable telomerase induction in human cell lines, including a 2025 Western-indexed independent replication [1][2]. In rodents: reduced spontaneous tumor frequency, lifespan effects in some cohorts but not others [4][6][9]. In humans: limited, mostly Russian-language data — real but not at the level of registered Western clinical trials [11][12][15]. ## Reported side effects in Epitalon studies ### What side effects have been reported in Epithalon studies? Russian cohort reports describe a generally favourable tolerability profile with no consistent severe adverse events documented across the published Epithalamin/Epitalon record [11][13]. Site-of-injection reactions are the most commonly mentioned issue. The 2025 Araj review explicitly notes that large, modern safety and toxicology data of the regulatory type are absent from the published literature [15]. ### What side effects have been reported with Epitalon? The peer-reviewed record reports a generally favourable tolerability profile in the Russian-program human cohorts and a clean rodent toxicity record in the long-duration studies tested (Kossoy 2006 reported no observable toxicity at 0.1 microgram/mouse five days/week for 6.5 months) [7][11]. Formal regulatory-grade toxicology, genotoxicity, and carcinogenicity packages are not in the public peer-reviewed literature [15]. ## Regulatory status of Epitalon ### Is Epitalon legal as a research chemical? Epitalon is not an FDA-approved drug in the United States for any human indication and is not approved by the EMA or other major Western regulators [15]. Outside Russia it is generally handled as a research chemical. In Russia, related pineal preparations have a history of use in geriatric medicine within the Khavinson program's institutional context [14]. Athletes should consult current WADA documentation directly. --- A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named.